Results 51 to 60 of about 62,419 (246)

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta-analysis. [PDF]

Diabetes Obes Metab
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Chen SH, Tseng YW, Huang CJ, Yang SM, Fudim M, Chuang SY, Sung SH, Cheng HM.   +7 more
europepmc   +2 more sources

Tissue digoxin concentrations and digoxin effect during the quinidine-digoxin interaction

Journal of the American College of Cardiology, 1985
Quinidine elevates serum digoxin concentration in part by reducing the volume of distribution of digoxin, which implies that quinidine displaces digoxin from tissues. The purposes of this study were to: 1) measure the effect of quinidine on tissue digoxin concentrations, and 2) determine if quinidine alters the relation between myocardial digoxin ...
Warner, Natalie J., Thomas Barnard, J., Thomas Bigger, J.   +2 more
openaire   +2 more sources

Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring

BMC Medicine, 2004
Background The ABC transporter P-glycoprotein (P-gp) is recognized as a site for drug-drug interactions and provides a mechanistic explanation for clinically relevant pharmacokinetic interactions with digoxin.
Michaëlsson Karl, Artursson Per, Hallberg Pär, Englund Gunilla, Melhus Håkan   +4 more
doaj   +1 more source

Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data

BMC Pharmacology and Toxicology, 2022
Background Digoxin is an important treatment option for reducing the ventricular rate in patients with atrial fibrillation (AF) and heart failure (HF). Digoxin has a narrow therapeutic window and large interindividual variability.
Toshinori Hirai, Hidefumi Kasai, Miyoko Naganuma, Nobuhisa Hagiwara, Tsuyoshi Shiga   +4 more
doaj   +1 more source

The effect of calcium in water hardness on digoxin plasma levels in an experimental rat model [PDF]

ARYA Atherosclerosis, 2020
BACKGROUND: Digoxin is a drug for ventricular rate control in atrial fibrillation (AF). The major challenge in digoxin therapy is to adjust the appropriate concentration range for this drug due to its narrow therapeutic index.
Shabnam Shahsavand, Mohammad Moshirfar, Seyed Hassan Seyed-Sharifi, Mohammad Amin Younessi-Heravi, Reza Ghasemi, Morteza Valaei, Mohsen Yaghubi   +6 more
doaj   +1 more source

Integrating Human Intestinal Organoids into FDA'S New Approach Methodologies for Drug Discovery

Advanced Science, EarlyView.
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee, Honit Piplani, Aida Habtezion, Michael J. Rosen, Jospeh C. Wu   +6 more
wiley   +1 more source

Improving Postdischarge Outcomes in Acute Heart Failure [PDF]

, 2018
The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P., Antohi, Elena-Laura, Butler, Javed, Chioncel, Ovidiu, Collins, Sean P., Iliescu, Vlad Anton, Maggioni, Aldo P., Mebazaa, Alexandre, Pang, Peter S.   +8 more
core   +1 more source

Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp. [PDF]

PLoS ONE, 2013
We have reported that the P-gp substrate digoxin required basolateral and apical uptake transport in excess of that allowed by digoxin passive permeability (as measured in the presence of GF120918) to achieve the observed efflux kinetics across MDCK-MDR1-
Annie Albin Lumen, Libin Li, Jiben Li, Zeba Ahmed, Zhou Meng, Albert Owen, Harma Ellens, Ismael J Hidalgo, Joe Bentz   +8 more
doaj   +1 more source

Adapting clinical guidelines to take account of multimorbidity [PDF]

, 2012
Most people with a chronic condition have multimorbidity, but clinical guidelines almost entirely focus on single conditions. It will never be possible to have good evidence for every possible combination of conditions, but guidelines could be made more ...
Alderson, P., Guthrie, B., McMurdo, M.E.T., Mercer, S.W., Payne, K.   +4 more
core   +1 more source

Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis [PDF]

, 2005
BACKGROUND AND AIMS: The MDR1 gene encodes P-glycoprotein 170, an efflux transporter that is highly expressed in intestinal epithelial cells. The MDR1 exonic single nucleotide polymorphisms (SNPs) C3435T and G2677T have been shown to correlate with ...
Arnott, Ian D, Drummond, Hazel, Fennell, Janice, Ho, Gwo-Tzer, Mowat, Craig, Nimmo, Elaine R, Satsangi, Jack, Tenesa, Albert   +7 more
core   +1 more source